Stockscreener 앱 받기
323.95
3.33%
10.45
시간 외 거래:
317.67
-6.28
-1.94%
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor - Stock Titan
Praxis Precision (PRAX) Partners with Remagine Labs for Innovati - GuruFocus
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - The Manila Times
Praxis bets on skin patch for essential tremor drug - Stock Titan
S&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN Lead - Barron's
PRAX stock. Praxis Precision Medicines holds the spotlight on thin news - AD HOC NEWS
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor - Stock Titan
Praxis uses inducement plan to grant 951 shares to five hires - Stock Titan
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Enterprise value to revenue forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
We Think Praxis Precision Medicines (NASDAQ:PRAX) Can Easily Afford To Drive Business Growth - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719 - Moomoo
The Technical Signals Behind (PRAX) That Institutions Follow - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $510 to $1,200 - Moomoo
Praxis sees encephalopathies asset relutrigine action date extended - MSN
PRAX Maintained by Needham -- Price Target Raised to $575 - GuruFocus
Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines (PRAX) Surges Nearly 7% as Momentum BuildsVolatility Stop - dars.gov.et
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Praxis Precision Medicines stock falls on FDA review delay By Investing.com - Investing.com South Africa
FDA Extends Review Timeline for Praxis’ Relutrigine NDA - TipRanks
Praxis Precision Medicines stock falls on FDA review delay - Investing.com UK
FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026 - Stock Titan
Praxis Precision Medicines Announces FDA Extends Review of Relutrigine NDA to December 27, 2026 - Quiver Quantitative
FDA delays Praxis relutrigine review by three months to Dec. 27 - Stock Titan
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell 3000E Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell Microcap Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Praxis gains FDA breakthrough therapy status for elsunersen for encephalopathy - MSN
Praxis Precision Medicines director Jill DeSimone sells $3.6m in shares - Investing.com Nigeria
Praxis Precision Medicines(PRAX.US) Director Sells US$3.61 Million in Common Stock - Moomoo
Form 4 Praxis Precision Medicines Inc For: 26 June By Investing.com - Investing.com South Africa
Praxis Precision Medicines Insider Sold Shares Worth $3,611,335, According to a Recent SEC Filing - marketscreener.com
Praxis (PRAX) director logs 11,600-share sale after option exercises - Stock Titan
Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree - Trefis
null - Trefis
Praxis Precision Medicines, Inc. Actuals & Estimates (BOATS:PRAX) - TradingView
Praxis Precision Medicines outlines next steps, shares trade quietly on Nasdaq - Ad-hoc-news.de
PRAX Forecast — Price Target — Prediction for 2027 - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, Quote, News & Analysis - Seeking Alpha
Form 144 Praxis Precision Medicines For: 24 June By Investing.com - Investing.com Australia
Form 144 | Praxis Precision Medicines(PRAX.US) Director Proposes to Sell 3.61 Million in Common Stocks - Moomoo
[144] Praxis Precision Medicines, Inc. SEC Filing - Stock Titan
Praxis Precision Medicines (PRAX): Best Upside Stocks to Buy According to Hedge Funds - Insider Monkey
Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen (PRAX) - Seeking Alpha
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $550 - Moomoo
5 Best Upside Stocks to Buy According to Hedge Funds - Insider Monkey
1.17%
2.48%
자본화:
|
볼륨(24시간):